Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100

…, J Balzarini, M Witvrouw, K De Vreese… - Antimicrobial agents …, 1994 - Am Soc Microbiol
Bicyclams, in which the cyclam (1,4,8,11-tetraazacyclotetradecane) moieties are tethered
via an aliphatic bridge (ie, propylene, as in JM2763) are potent and selective inhibitors of …

Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia

S Engelborghs, K De Vreese, T Van de Casteele… - Neurobiology of …, 2008 - Elsevier
To establish diagnostic performance of the cerebrospinal fluid (CSF) biomarkers β-amyloid
peptide (Aβ 1–42 ), total tau-protein (T-tau) and tau phosphorylated at threonine 181 (P-tau …

Synthesis and structure-activity relationships of phenylenebis (methylene)-linked bis-tetraazamacrocycles that inhibit HIV replication. Effects of macrocyclic ring size …

…, MJ Abrams, N Yamamoto, KD Vreese - Journal of medicinal …, 1995 - ACS Publications
We have previously described the potent and selective inhibition of several strains of
human immunodeficiency virus type 1 (HIV-1) and type 2 (HIV-2) by JM2763, an «-propyl-linked …

Analytical performance and clinical utility of the INNOTEST® PHOSPHO-TAU(181P) assay for discrimination between Alzheimer's disease and dementia with Lewy …

H Vanderstichele, K De Vreese, K Blennow… - Clinical Chemistry and …, 2006 - degruyter.com
Background: Total tau (T-tau) and β-amyloid (1-42) (Aβ 1-42 ) levels in cerebrospinal fluid (CSF)
can differentiate Alzheimer's disease (AD) from normal aging or depressive pseudo-…

Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay

…, G Maertens, F Hulstaert, K De Vreese… - Journal of Clinical …, 2002 - Am Soc Microbiol
Sensitive and early detection of emerging hepatitis B virus (HBV) drug resistance may not
only help monitor the viral dynamics associated with lamivudine treatment but could also …

Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of alpha-anilinophenylacetamide derivatives targeted at HIV-1 reverse …

…, D Schols, P Stoffels, K De Vreese… - Proceedings of the …, 1993 - National Acad Sciences
In vitro evaluation of a large chemical library of pharmacologically acceptable prototype
compounds in a high-capacity, cellular-based screening system has led to the discovery of …

The molecular target of bicyclams, potent inhibitors of human immunodeficiency virus replication

K De Vreese, V Kofler-Mongold, C Leutgeb… - Journal of …, 1996 - Am Soc Microbiol
Bicyclams are a novel class of antiviral compounds which act as potent and selective inhibitors
of the replication of human immunodeficiency virus type 1 (HIV-1) and HIV-2. They block …

T30177, an oligonucleotide stabilized by an intramolecular guanosine octet, is a potent inhibitor of laboratory strains and clinical isolates of human immunodeficiency …

…, Y Pommier, A Mazumder, K De Vreese… - Antimicrobial agents …, 1995 - Am Soc Microbiol
T30177, an oligonucleotide composed of only deoxyguanosine and thymidine, is 17 nucleotides
in length and contains single phosphorothioate internucleoside linkages at its 5' and 3' …

Development of resistance of human immunodeficiency virus type 1 to dextran sulfate associated with the emergence of specific mutations in the envelope gp120 …

JA Esté, D Schols, K De Vreese, K Van Laethem… - Molecular …, 1997 - ASPET
Polyanionic compounds are known to inhibit the binding of human immunodeficiency virus (HIV)
to CD4 + cells and the subsequent fusion step between the virus and cells. We selected …

The bicyclams, a new class of potent human immunodeficiency virus inhibitors, block viral entry after binding

K De Vreese, D Reymen, P Griffin, A Steinkasserer… - Antiviral research, 1996 - Elsevier
The bicyclams represent a new class of highly potent and selective HIV inhibitors. Time-of-addition
experiments have previously shown that these compounds interfere with an early …